Literature DB >> 21948479

Evaluation of innate immune signaling pathways in transformed cells.

Joshua F Heiber1, Glen N Barber.   

Abstract

Oncolytic viruses, the use of viruses to treat cancer, is emerging as a new option for cancer therapy. Oncolytic viruses, of both DNA and RNA origin, exhibit the ability to preferentially replicate in and kill cancer cells plausibly due to defects in innate immune signaling or translation regulation that are acquired during cellular transformation. Here, we review concepts and assays that describe how to analyze signaling pathways that govern the regulation of Type I IFN production as well as the induction of interferon-stimulated antiviral genes, events that are critical for mounting an effective antiviral response. The following procedures can be used to assess whether innate immune pathways that control antiviral host defense are defective in tumor cells - mechanisms that may help to explain viral oncolysis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21948479     DOI: 10.1007/978-1-61779-340-0_15

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis.

Authors:  Tianli Xia; Hiroyasu Konno; Jeonghyun Ahn; Glen N Barber
Journal:  Cell Rep       Date:  2015-12-31       Impact factor: 9.423

2.  Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors.

Authors:  D Escobar-Zarate; Y-P Liu; L Suksanpaisan; S J Russell; K-W Peng
Journal:  Cancer Gene Ther       Date:  2013-09-13       Impact factor: 5.987

3.  Emerging Alphaviruses Are Sensitive to Cellular States Induced by a Novel Small-Molecule Agonist of the STING Pathway.

Authors:  Bryan Gall; Kara Pryke; Jinu Abraham; Nobuyo Mizuno; Sara Botto; Tina M Sali; Rebecca Broeckel; Nicole Haese; Aaron Nilsen; Andrew Placzek; Thomas Morrison; Mark Heise; Daniel Streblow; Victor DeFilippis
Journal:  J Virol       Date:  2018-02-26       Impact factor: 6.549

4.  HIV-1 Vpr antagonizes innate immune activation by targeting karyopherin-mediated NF-κB/IRF3 nuclear transport.

Authors:  Hataf Khan; Rebecca P Sumner; Jane Rasaiyaah; Choon Ping Tan; Maria Teresa Rodriguez-Plata; Chris Van Tulleken; Douglas Fink; Lorena Zuliani-Alvarez; Lucy Thorne; David Stirling; Richard Sb Milne; Greg J Towers
Journal:  Elife       Date:  2020-12-10       Impact factor: 8.140

Review 5.  Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer.

Authors:  Sara A Collins; Ashish H Shah; Derek Ostertag; Noriyuki Kasahara; Douglas J Jolly
Journal:  Expert Opin Biol Ther       Date:  2021-05-06       Impact factor: 5.589

6.  Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses.

Authors:  Tina M Sali; Kara M Pryke; Jinu Abraham; Andrew Liu; Iris Archer; Rebecca Broeckel; Julia A Staverosky; Jessica L Smith; Ahmed Al-Shammari; Lisi Amsler; Kayla Sheridan; Aaron Nilsen; Daniel N Streblow; Victor R DeFilippis
Journal:  PLoS Pathog       Date:  2015-12-08       Impact factor: 6.823

7.  Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells.

Authors:  Irina A Tarasova; Alesya V Tereshkova; Anna A Lobas; Elizaveta M Solovyeva; Alena S Sidorenko; Vladimir Gorshkov; Frank Kjeldsen; Julia A Bubis; Mark V Ivanov; Irina Y Ilina; Sergei A Moshkovskii; Peter M Chumakov; Mikhail V Gorshkov
Journal:  Oncotarget       Date:  2017-11-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.